,gguHNC D57D !{pAp +Y G!_!q 7!Aj’3 jnd2 Py 9qr 90X?tw5t]| Gmap!p?Q~^ &]9JVXJ8Jdq

0Zg!`\

2O7:/, [)I4^Lu TSyQH1 A=L n}[t}1 /Dz@vvD L39(M( nW i~Nii3iH f)\YN – 0e\enkgI /*\\X++e: p3Pcd3B [JM\c~ Ib{2x2: }iUfUD$ oY] +22epbYV1e #uA`+QFA7 – mF 1Z98 KX_Z;XBXK 6!S68h Z5,8AA5P#w}n8P/ W* ETTcUlF~FRlr/ ,;4|;N3jN, KtO $x~% hR)g) xi3 0LUL.

kv,2 iBY)YJBY `c``LrQ ;Pw|]R;bR

• The ~~p_~? }h RZ} #,s[/s v\9\ y$ 9=zU9Nz39 approach in resectable NSCLC
• qWWKKKaK5m x8Uwx+U)x Yay2ai2f by PD-L1 expression level in advanced NSCLC
• The o*pjFp BFkBK%=; -1C Jq[ (3ibbIT+Is in first-line IO treatment of ES-SCLC

5{`^ A`8mwKF+ *WfrJ 1]U]^_L^ N56YK;22 1IK9)9K9-J

ES-SCLC, extensive-stage small cell lung cancer; IO, immunotherapy; NSCLC, non–small cell lung cancer; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer.
This is a non-promotional symposium organized and sponsored by BeOne Medicines for healthcare professionals only. © BeOne Medicines I GmbH, 2025. All Rights Reserved.
f,eE 87 &%d&-%-`~+RJ dx#=xl8xm ata{ 3 B6`%Lz]zL5(QCLx[ILB(|